POLB Stock Overview
Operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Poolbeg Pharma PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.083 |
| 52 Week High | UK£0.16 |
| 52 Week Low | UK£0.07 |
| Beta | 2.14 |
| 11 Month Change | 0% |
| 3 Month Change | -36.15% |
| 1 Year Change | -10.75% |
| 33 Year Change | -20.00% |
| 5 Year Change | n/a |
| Change since IPO | -22.79% |
Recent News & Updates
Recent updates
Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth
Aug 20
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Feb 16We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Oct 05We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely
Jun 01Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation
Jul 12Shareholder Returns
| POLB | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -5.9% | -1.0% | -0.1% |
| 1Y | -10.8% | -4.0% | 5.5% |
Return vs Industry: POLB underperformed the UK Pharmaceuticals industry which returned -4% over the past year.
Return vs Market: POLB underperformed the UK Market which returned 5.5% over the past year.
Price Volatility
| POLB volatility | |
|---|---|
| POLB Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: POLB has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: POLB's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 15 | Jeremy Skillington | www.poolbegpharma.com |
Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Poolbeg Pharma PLC Fundamentals Summary
| POLB fundamental statistics | |
|---|---|
| Market cap | UK£41.50m |
| Earnings (TTM) | -UK£4.38m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.5x
P/E RatioIs POLB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| POLB income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£4.38m |
| Earnings | -UK£4.38m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0088 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did POLB perform over the long term?
See historical performance and comparison